Halozyme Therapeutics Inc (NASDAQ:[HALO](https://www.chartmill.com/stock/quote/HALO)): A Strong Affordable Growth Candidate

Affordable growth stocks combine solid financial health, strong profitability, and reasonable valuations with above-average growth potential. These stocks often appeal to investors looking for companies that can deliver consistent earnings expansion without overpaying for future performance.

Halozyme Therapeutics Inc (NASDAQ:HALO) stands out as a compelling candidate in this category. The company, a biopharmaceutical technology platform firm, specializes in drug delivery solutions and has demonstrated strong financial metrics.

Why HALO Fits the Affordable Growth Criteria

1. Strong Growth (Rating: 8/10)

   • Revenue has grown at an average of 38.95% over recent years, with earnings per share (EPS) increasing by 30.12% annually.
   • Future estimates suggest continued growth, with EPS expected to rise by 16.06% per year.

2. Solid Profitability (Rating: 8/10)

   • The company boasts a high return on equity (122.06%) and return on invested capital (23.00%), outperforming most peers.
   • Operating margins (54.32%) and profit margins (43.74%) are well above industry averages.

3. Healthy Financials (Rating: 8/10)

   • A strong current ratio (7.80) and quick ratio (6.78) indicate good liquidity.
   • The Altman-Z score (4.82) suggests low bankruptcy risk.

4. Attractive Valuation (Rating: 9/10)

   • With a P/E ratio of 14.24, HALO trades at a discount compared to both the industry (86.79) and the S&P 500 (28.98).
   • The forward P/E of 11.41 further supports its reasonable valuation.

For a deeper dive into HALO’s fundamentals, review the full analysis report here.

Affordable Growth Screen Results

This stock was identified using an "Affordable Growth" screen, which filters for companies with strong growth, solid profitability, and reasonable valuations. To explore similar opportunities, check the stock screener results.